transform
hillrom deliv strong provid lrp
guidanc larg in-lin slightli ahead expect
 like continu shift wamgr core
non-cor confus fade digit em contribut
increas multipl rise pt
follow recent healthcar confer quarter
result even stronger hillrom report revenu
vs mse compani deliv core growth pt vs mse
includ bp voalt breath immateri result impli
core growth rel core growth guidanc last updat
increment bp driven equal voalt upsid
broader-bas strength across patient support system pss surgic
solut ss underli basi result demonstr organ
growth pt upsid versu mse quarter pss deliv
revenu pt vs mse driven strength across centrella
connect care ss deliv pt vs mse record quarter
tabl motion placement front line flc pt vs mse weaker
primarili due difficult comp tie pent-up demand ahead
monarch us launch although encourag return growth
cc underli intern busi new leadership
quarter vs mse om vs mse
larg in-lin estim bottom-lin beat ep vs
mse larg top-line driven pleas seeexhibit full reconcili
top-line guidanc come ahead hillrom guid core growth
inclus breath voalt acquisit rel core
growth guidanc expect differ
acquisit contribut vs previou model
increment worth pt growth breath
voalt contribut bp growth
voalt breath revenu larg back-half weight
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
breath voalt surgic oem drive differ core
organ model organ growth repres
declin driven oem exit
area potenti upsid includ new product launch
slate drive bp hillrom capac
expand net debt/ebitda current repres
capac emerg market acceler hillrom
deliv hsd em growth expect grow hsd
doubl digit em growth could drive bp upsid
ep growth guidanc consist preview addit
guidanc larg in-lin expect guidanc bp
gross margin expans impli pt ahead
model higher invest yield guidanc oper margin in-
line expect consist om expans compani
deliv sinc tax expens
reflect interest expens reduct hillrom debt
offer share count consist model manag
outlin plan reach report ep growth preview
double-digit earnings-growth ex-impact surgic
consum divestitur also in-lin preview
lrp reflect conservat expect conserv
guidanc aggress lrp got revers said
encourag manag outlin see multipl lever
hillrom achiev lrp upsid includ addit especi true
digit becom meaning driver busi patient
commun inclus voalt contribut revenu
segment like key focu futur acquisit manag expect
stabl macro hospit spend environ deceler
centrella growth hsd growth lsd-msd growth
view assumpt prudent note hillrom track meet
although lrp guidanc new leadership
confid hillrom abil execut lrp pleas see
exhibit rel differ hillrom lrp vs prior lrp
provid
exhibit compar hillrom lrp
use midpoint
use midpoint
use midpoint
new product
revenu
deliv
use midpoint
hillrom continu make progress toward becom durabl faster
grow busi pt remain encourag hillrom direct
continu see execut new product launch em addit
acquisit necessari shift wamgr toward durabl dynam
core non-cor growth continu obscur underli
fundament see converg core cc growth metric
posit result indic underli
perform improv strong contribut voalt well
expect breath impli strategi cohes rais price
target reflect ebitda multipl discount
smid coverag move past non-cor dynam digit solut continu
contribut meaning growth emerg market show
improv multipl could expand bia hillrom continu
multipl potenti re-rat given improv growth
multipl potenti re-rat given improv growth
price target reflect ev/ebitda multipl
discount smid cap med-tech given leverag lower growth
new product launch growth exceed expect cost initi
take margin higher new product launch perform better expect
underli margin surpass top hill-rom lrp driven revenu upsid
mix cost initi hill-rom manag remain focus addit
deal compani de-lev
hill-rom growth stabil mid-singl digit pipelin product move hill-
rom structur organ growth rate mid singl digit time
compani execut lrp emerg market begin inflect improv
stabil growth visibl margin improv drive multipl
long-term plan materi sale see moder growth
slowdown capital-expenditure environ hurt pss pipelin fail
materi expect initi manifest plan along
top-line shortfal drive limit margin improv
multipl fall lrp fail materi
hill-rom multipl re-rat
growth move higher volatil
decreas hill-rom sale base
diversifi number driver
increas hill-rom organ
growth rate divestitur non-cor product
hill-rom new lrp call cc growth
growth along
annual om expans
adjust ep compound-annual-growth-rate see new
lrp achiev product pipelin
remain robust end market mix
digit improv
hospit capital-expenditure environ hill-
rom revenu expos hospit
motion connex centrella contribut
sale
 deal shift wamgr higher
progress cost restructur
on-going uptak recent product
risk achiev price
pipelin traction slow fail
materi upcom product
margin leverag prove difficult
materi shift capital-expenditure environ
million except ep
product sale servic
good sold
dollar million except per share data
total revenu
less net incom non-controlling interest
net incom sharehold
restat
dollar million except per share data
dollar million except per share data
invest invest secur
softwar net
note receiv net discount
accru pension postretir benefit
addit paid capit
dollar million except per share data
net realiz capit loss gain equiti method invest incom loss
provis defer incom tax
chang oper asset liabil
net provid oper activ
capit expenditur purchas intang
proce dispos properti equip leas
proce sale non-strateg asset
payment acquisit busi net cash
invest purchas capit call
proce invest sale matur
net use invest activ
net chang short-term debt net debt issuanc cost
payment long-term debt net proce settlement interest rate swap includ payment/borrow revolv
distribut non-controlling interest partner
net chang equiti
effect exchang rate ce
net chang
equival bop
equival eop
